9 Sep 2020 07:00
Yourgene Health plc
("Yourgene" or the "Group" or the "Company")
AGM update and investor presentation
Manchester, UK - 9 September 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that further to the Notice of AGM issued on 28 August 2020, the Company announces details of how to join the AGM, which is to be held virtually via Investor Meet Company platform on 22 September 2020 at 4.00pm. All existing and potential shareholders are invited and encouraged to join.
The Company's CEO, Lyn Rees, will provide shareholders with a short presentation after the formal business of the AGM concludes and there will be an opportunity for investors to ask questions. As previously announced, all voting must be done via proxy ahead of the meeting - for further details see the RNS issued by Yourgene on 28 August 2020 https://bit.ly/357KsDo.
The Company is committed to ensuring that there are appropriate communication structures for all elements of its shareholder base so that its strategy, business model and performance are clearly understood.
Questions can be submitted pre-event via your IMC dashboard or at any time during the live presentation via the "Ask a Question" function. Although the Company may not be in a position to answer every question it receives, it will address the most prominent within the confines of information already disclosed to the market. Responses to the Q&A from the live presentation will be published at the earliest opportunity on the Investor Meet Company platform.
Investors can sign up to Investor Meet Company for free and add to meet Yourgene Health via:
https://www.investormeetcompany.com/yourgene-health-plc/register-investor
Investors who have already registered for the Investor Meet Company platform and added to meet the Company will be automatically invited.
Investors who have already registered via Walbrook PR, are encouraged to sign up to the IMC platform.
Yourgene Health plc Lyn Rees, Chief Executive Officer | Tel: +44 (0)161 669 8122 investors@yourgene-health.com | ||
Barry Hextall, Chief Financial Officer |
| ||
Joanne Cross, Director of Marketing |
| ||
|
| ||
Cairn Financial Advisers LLP (NOMAD) | Tel: +44 (0)20 7213 0880 | ||
Liam Murray / James Caithie / Ludovico Lazzaretti |
| ||
|
| ||
N+1 Singer (Joint Corporate Broker) | Tel: +44 (0)20 7496 3000 | ||
Aubrey Powell / Tom Salvesen / George Tzimas |
| ||
|
| ||
Stifel Nicolaus Europe Limited (Joint Corporate Broker) | Tel: +44 (0)20 7710 7600 | ||
Nicholas Moore / Matthew Blawat / Ben Maddison |
| ||
|
| ||
|
| ||
Walbrook PR Ltd (Media and Investor Relations) | Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com | ||
Paul McManus / Lianne Cawthorne | Mob: 07980 541 893 / Mob: 07584 391 303 | ||
|
|
| |
About Yourgene Health plc
Yourgene is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.
Yourgene develops and commercialises simple and accurate molecular diagnostic solutions, for reproductive health and molecular genetics. The Group's products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, male infertility tests and genetic disease tests. Yourgene's commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.
Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions. Through our technical expertise and partnerships, Yourgene is also extending its genetic testing offering into oncology.
Yourgene is headquartered in Manchester, UK with offices in Taipei and Singapore, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information, visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.